{"success":true,"data":{"pressRelease":{"id":"6546","rtpr_id":"nGNX1htPJc","ticker":"SLNO","exchange":"NASDAQ","all_tickers":["SLNO"],"title":"SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)","author":"Globe Newswire","published_at":"2026-04-23T12:01:00.576Z","article_body":"NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP\n(https://www.globenewswire.com/Tracker?data=Mz2XiHVT-iTA3zhTqvQUBgOyTgCvlTwpCAcEH0gwQAY8U2Y-JOCD_dzUobb4otWWpGhji8SilY1q-4eSHMgVYBuZ6n2M1opiGfIT1jnWgDc=)\nannounces that a shareholder has filed a securities class action lawsuit on\nbehalf of investors (the “Class”) who purchased or acquired the common\nstock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”)\n(NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.\n\nShould You Join The Soleno Class Action Lawsuit?\n* Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?\n\n\n* Did you purchase your shares between March 26, 2025 and August 4, 2025,\ninclusive?\n\n\n* Did you lose money in your investment in Soleno Therapeutics, Inc.?\nWhat To Do Next:\n\nIf you purchased or acquired Soleno common stock, and/or would like to\ndiscuss your legal rights and options please visit Soleno Therapeutics, Inc.\nShareholder Class Action Lawsuit\n(https://www.globenewswire.com/Tracker?data=2TjGqYv1Dpc9ez6NdgDT6nyMC6zH9zRYng_uZYExdegIUMBOtpi4SacjxAJ5E4homihTH22TEzDH9_kvtM4AkZoNsEkZqy2qN_721DLZNQccz-2yOfoIciP59Uzr5hR23xrgWcJCzcpdKtoynbMlYKvbmbs3Lfau0xMHYSo2VImIa1yTqXxdSkpAj453tED5Gotgci8nl7WS8_EL-A5FTYrq6lKws4_MQIRolaNfPbNbNonX1cSQRNWSz1Zl7zLa)\nor contact Investor Relations Manager Peter Allocco at (212)\n951-2030 or pallocco@bernlieb.com.\n\nIf you wish to serve as lead plaintiff for the Class, you must file papers by\nMay 5, 2026. A lead plaintiff is a representative party acting on other class\nmembers’ behalf in directing the litigation. Your ability to share in any\nrecovery doesn’t require that you serve as lead plaintiff. If you choose to\ntake no action, you may remain an absent class member.\n\nAll representation is on a contingency fee basis. Shareholders pay no fees or\nexpenses.\n\nAbout The Lawsuit:\n\nAccording to the lawsuit, Defendants made misrepresentations concerning the\nCompany's Phase 3 clinical trial program for DCCR.\n\nAbout Bernstein Liebhard:\n\nSince 1993, Bernstein Liebhard LLP\n(https://www.globenewswire.com/Tracker?data=Mz2XiHVT-iTA3zhTqvQUBgOyTgCvlTwpCAcEH0gwQAYQUJrcU4W0gyy_jPHJIY4B3oU9Nsu6iZbLDgINJEk5eDvXjjqRHuXY4ah9vxQThYQ=)\nhas recovered over $3.5 billion for its clients. In addition to representing\nindividual investors, the Firm has been retained by some of the largest public\nand private pension funds in the country to monitor their assets and pursue\nlitigation on their behalf. As a result of its success litigating hundreds of\nclass actions, the Firm has been named to The National Law Journal’s\n“Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for\nsixteen consecutive years.\n\nATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible\nfor this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New\nYork, New York 10016, (212) 779-1414. Prior results do not guarantee or\npredict a similar outcome with respect to any future matter.\n\nContact Information:\n\nPeter Allocco\nInvestor Relations Manager\nBernstein Liebhard LLP\nhttps://www.bernlieb.com\n(212) 951-2030\npallocco@bernlieb.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5d514042-8326-4555-8ad7-f6cc765ecfcd)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX1htPJc","title":"SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Class Action Lawsuit Has Been Filed Against Soleno Therapeutics, Inc. (SLNO)","author":"Globe Newswire","ticker":"SLNO","created":"2026-04-23T12:01:00.576Z","tickers":["SLNO"],"exchange":"NASDAQ","article_body":"NEW YORK, April 23, 2026 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP\n(https://www.globenewswire.com/Tracker?data=Mz2XiHVT-iTA3zhTqvQUBgOyTgCvlTwpCAcEH0gwQAY8U2Y-JOCD_dzUobb4otWWpGhji8SilY1q-4eSHMgVYBuZ6n2M1opiGfIT1jnWgDc=)\nannounces that a shareholder has filed a securities class action lawsuit on\nbehalf of investors (the “Class”) who purchased or acquired the common\nstock of Soleno Therapeutics, Inc. (“Soleno” or the “Company”)\n(NASDAQ: SLNO) between March 26, 2025 and August 4, 2025, inclusive.\n\nShould You Join The Soleno Class Action Lawsuit?\n* Do you, or did you, own shares of Soleno Therapeutics, Inc. (NASDAQ: SLNO)?\n\n\n* Did you purchase your shares between March 26, 2025 and August 4, 2025,\ninclusive?\n\n\n* Did you lose money in your investment in Soleno Therapeutics, Inc.?\nWhat To Do Next:\n\nIf you purchased or acquired Soleno common stock, and/or would like to\ndiscuss your legal rights and options please visit Soleno Therapeutics, Inc.\nShareholder Class Action Lawsuit\n(https://www.globenewswire.com/Tracker?data=2TjGqYv1Dpc9ez6NdgDT6nyMC6zH9zRYng_uZYExdegIUMBOtpi4SacjxAJ5E4homihTH22TEzDH9_kvtM4AkZoNsEkZqy2qN_721DLZNQccz-2yOfoIciP59Uzr5hR23xrgWcJCzcpdKtoynbMlYKvbmbs3Lfau0xMHYSo2VImIa1yTqXxdSkpAj453tED5Gotgci8nl7WS8_EL-A5FTYrq6lKws4_MQIRolaNfPbNbNonX1cSQRNWSz1Zl7zLa)\nor contact Investor Relations Manager Peter Allocco at (212)\n951-2030 or pallocco@bernlieb.com.\n\nIf you wish to serve as lead plaintiff for the Class, you must file papers by\nMay 5, 2026. A lead plaintiff is a representative party acting on other class\nmembers’ behalf in directing the litigation. Your ability to share in any\nrecovery doesn’t require that you serve as lead plaintiff. If you choose to\ntake no action, you may remain an absent class member.\n\nAll representation is on a contingency fee basis. Shareholders pay no fees or\nexpenses.\n\nAbout The Lawsuit:\n\nAccording to the lawsuit, Defendants made misrepresentations concerning the\nCompany's Phase 3 clinical trial program for DCCR.\n\nAbout Bernstein Liebhard:\n\nSince 1993, Bernstein Liebhard LLP\n(https://www.globenewswire.com/Tracker?data=Mz2XiHVT-iTA3zhTqvQUBgOyTgCvlTwpCAcEH0gwQAYQUJrcU4W0gyy_jPHJIY4B3oU9Nsu6iZbLDgINJEk5eDvXjjqRHuXY4ah9vxQThYQ=)\nhas recovered over $3.5 billion for its clients. In addition to representing\nindividual investors, the Firm has been retained by some of the largest public\nand private pension funds in the country to monitor their assets and pursue\nlitigation on their behalf. As a result of its success litigating hundreds of\nclass actions, the Firm has been named to The National Law Journal’s\n“Plaintiffs’ Hot List” thirteen times and listed in The Legal 500 for\nsixteen consecutive years.\n\nATTORNEY ADVERTISING. © 2026 Bernstein Liebhard LLP. The law firm responsible\nfor this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New\nYork, New York 10016, (212) 779-1414. Prior results do not guarantee or\npredict a similar outcome with respect to any future matter.\n\nContact Information:\n\nPeter Allocco\nInvestor Relations Manager\nBernstein Liebhard LLP\nhttps://www.bernlieb.com\n(212) 951-2030\npallocco@bernlieb.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/5d514042-8326-4555-8ad7-f6cc765ecfcd)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-04-23T12:01:00.615997351Z","server_sent_at_ms":1776945660615},"received_at":"2026-04-23T12:01:00.667Z","source_url":null},"analysis":{"id":"4791","press_release_id":"6546","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["securities class action lawsuit filed","allegations of misrepresentation regarding Phase 3 clinical trial program"],"eventType":"legal_litigation","narrative":"Bernstein Liebhard LLP announced that a securities class action lawsuit has been filed against Soleno Therapeutics on behalf of investors who purchased common stock between March 26, 2025 and August 4, 2025.\n\nThe lawsuit alleges that the defendants made misrepresentations concerning the Company's Phase 3 clinical trial program for DCCR.\n\nAffected investors have until May 5, 2026 to move for lead plaintiff appointment in the litigation.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"Class action lawsuit targets Soleno over alleged misrepresentations of its Phase 3 DCCR trial data."},"keyFigures":{},"quotedText":"","namedEntities":{"people":[{"name":"Peter Allocco","role":"Investor Relations Manager"}],"products":["DCCR"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO"},{"name":"Bernstein Liebhard LLP","relationship":"plaintiff counsel"}],"dollarAmounts":[{"amount":"$3.5 billion","context":"amount recovered for clients by Bernstein Liebhard since 1993"}]},"materialImpact":{"score":4,"reasoning":"A securities class action lawsuit has been filed alleging misrepresentations regarding the company's Phase 3 clinical trial program for DCCR, which is a core business asset."},"tickerRelevance":{"others":[],"primary":"SLNO"},"eventTypeSecondary":[]},"event_type":"legal_litigation","event_type_secondary":null,"sentiment":"bearish","material_impact_score":4,"narrative":"Bernstein Liebhard LLP announced that a securities class action lawsuit has been filed against Soleno Therapeutics on behalf of investors who purchased common stock between March 26, 2025 and August 4, 2025.\n\nThe lawsuit alleges that the defendants made misrepresentations concerning the Company's Phase 3 clinical trial program for DCCR.\n\nAffected investors have until May 5, 2026 to move for lead plaintiff appointment in the litigation.","key_figures":{},"named_entities":{"people":[{"name":"Peter Allocco","role":"Investor Relations Manager"}],"products":["DCCR"],"companies":[{"name":"Soleno Therapeutics, Inc.","ticker":"SLNO"},{"name":"Bernstein Liebhard LLP","relationship":"plaintiff counsel"}],"dollarAmounts":[{"amount":"$3.5 billion","context":"amount recovered for clients by Bernstein Liebhard since 1993"}]},"model_name":"glm-4.7","prompt_hash":"sha256:2f2748f0fcc8c4f2","schema_hash":"sha256:ad96b863d7123008","created_at":"2026-04-23T16:16:39.066Z","global_importance":3,"audience_relevance":3,"importance_components":{"method":"backfill-heuristic","signals":{"bodyLong":false,"headlineTier1":false,"tickerCovered":false,"hadSignificance":false},"version":1,"computedAt":"2026-04-27T11:52:54.754Z"}},"durationMs":191128,"modelName":"glm-4.7"}}